主催: The Japanese Pharmacological Society, The Japanese Society of Clinical Pharmacology
会議名: WCP2018 (18th World Congress of Basic and Clinical Pharmacology)
開催地: Kyoto
開催日: 2018/07/01 - 2018/07/06
Background: Tizanadin is been evaluated as a novel drug candidate for treating depression using Mice. The various limitations of presently available antidepressants stress the need for improve pharmacotherapy intervention. Tizanadin may be a potent new therapeutic option for depression because studies have shown that Alpha 2 adrenergic receptor activation contributes to the antidepressants effect of Noradrenalin reuptake inhibitors like Desipramine, suggesting the possibility of Tizanadin as a good antidepressant.
Method: Tail suspension test (TST) and Force swim test (FST) were used as antidepressant screening test. The mice were treated with: 10mg/kg distilled water(Group 1), 15mg/kg Imipramine (Group 2), 4mg/kg Tizanadin(Group 3), 2mg/kg Tizanadin(Group 4), and 1mg/kg Tizanadin (Group 5) intraperitonially. Test for stimulant activity was evaluated using open field test(OFT).
Results: Tizanadine produce significant antidepressant like effect at all dose tested as indicated by reduction in immobility time of mice in FST and TST(p< 0.05). The efficacy of Tizanadine were found to be comparable to Impiramine 15mg/Kg. There was no significant increase in number of line crossed in OFT.
Conclusion: Tizanadin possesses significant antidepressant like effect.